Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Summary of Earnings Per Share, Basic and Diluted

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts):

	For the Three Months Ended March 31,
	2024		2023
Numerator
Consolidated net (loss)/income	$	(4,273)	$	509,089
Less: Net income attributable to continuing non-controlling interests	1,539		123,257
Less: Net (loss)/income attributable to legacy non-controlling interests	(10,590)		45,077
Net income attributable to Royalty Pharma plc - basic	4,778		340,755
Add: Reallocation of net income attributable to non-controlling interests from the assumed conversion of Class B ordinary shares	1,539		123,257
Net income attributable to Royalty Pharma plc - diluted	$	6,317	$	464,012
Denominator
Weighted average Class A ordinary shares outstanding - basic	448,623		445,612
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares	148,812		161,612
Unvested RSUs	44		27
Weighted average Class A ordinary shares outstanding - diluted	597,479		607,251
Earnings per Class A ordinary share - basic	$	0.01	$	0.76
Earnings per Class A ordinary share - diluted	$	0.01	$	0.76